Nonviolent Communication for Parents
Launched by HONG KONG METROPOLITAN UNIVERSITY · Apr 17, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special communication method called Nonviolent Communication (NVC) can help improve the mental well-being of parents. Specifically, it aims to see if this approach can reduce stress, anxiety, and depression in parents while also helping their children with emotional and behavioral issues. The trial will involve 172 parents who have children in primary school. These parents will be randomly divided into two groups: one group will take part in six weekly training sessions on NVC, while the other group will wait and receive the training later.
To be eligible for this trial, parents must be between 24 and 59 years old, have children of primary school age, and experience mild to severe symptoms of depression or anxiety. Participants should also be residents of Hong Kong and able to understand Cantonese. Throughout the trial, participants will complete surveys to measure their mental health and experiences with NVC at different points in time. After the training, the waitlist group will also get the chance to attend the sessions. The trial aims to provide valuable insights into how NVC can support parents and improve their families' overall well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) parents aged 24-59 years with children of primary school age;
- • 2) with mild to severe depressive symptoms (score \>5 on the Patient Health Questionnaire (PHQ)-9) (Kroenke et al., 2001) and/or mild to severe anxiety symptoms (score \>5 on the General Anxiety Disorder (GAD)-7) (Spitzer et al., 2006); and
- • 3) Hong Kong residents who can understand Cantonese.
- Exclusion Criteria:
- • 1) under psychiatric treatment, psychotherapy groups and are classified as unstable cases based on the judgment of the recruiting social workers;
- • 2) participating in other related parenting programmes.
About Hong Kong Metropolitan University
Hong Kong Metropolitan University (HKMU) is a leading institution committed to advancing research and education in various fields, including health sciences. As a clinical trial sponsor, HKMU leverages its robust academic resources and expertise to facilitate innovative research initiatives aimed at improving patient care and health outcomes. The university fosters collaboration among multidisciplinary teams, ensuring adherence to rigorous ethical standards and regulatory compliance throughout the research process. HKMU's commitment to excellence in clinical research not only enhances its academic reputation but also contributes significantly to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Grace Yuying Sun
Principal Investigator
Hong Kong Metropolitan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported